Hypertension - Pipeline Review, Q4 2010Global Markets DirectDecember 8, 2010 147 Pages - SKU: GMD6045501 |
- Introduction
- Global Markets Direct Report Coverage
- Hypertension Overview
- Therapeutics Development
- An Overview of Pipeline Products for Hypertension
- Hypertension Therapeutics under Development by Companies
- Hypertension Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Companies Involved in Hypertension Therapeutics Development
- Boehringer Ingelheim GmbH
- Abbott Laboratories
- Shionogi & Co., Ltd.
- Sanofi-Aventis
- Gilead Sciences, Inc.
- Daiichi Sankyo Company, Ltd
- Merck & Co., Inc.
- MicroDose Technologies, Inc.
- Dainippon Sumitomo Pharma Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Plexxikon Inc.
- Novartis AG
- Chong Kun Dang Pharmaceutical
- Daewoong Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Recordati S.p.A.
- Sigma-Tau S.p.A.
- Eurand N.V.
- Ligand Pharmaceuticals Incorporated
- Medicure Inc.
- Medivir AB
- NicOx SA
- Compugen Ltd.
- Palatin Technologies, Inc.
- Yuhan Corporation
- Boryung Pharmaceutical Co., Ltd.
- Hanall Pharmaceutical Co., Ltd.
- Cytos Biotechnology AG
- LG Life Sciences, Ltd
- AFFiRiS AG
- Respiratorius AB
- Arete Therapeutics Inc.
- Circ Pharma Limited
- Surface Logix, Inc.
- QUANTUM GENOMICS Corp.
- Ferrer Internacional S.A.
- Targacept, Inc.
- Bial Group
- Diakron Pharmaceuticals, Inc.
- Biolink Group AS
- Cellceutix Pharmaceuticals, Inc.
- KemPharm, Inc.
- Sorbent Therapeutics, Inc.
- Mayo Clinic
- Eurofarma
- Asklepion Pharmaceuticals, LLC.
- Serodus AS
- Universities/Institutes Involved in Hypertension Therapeutics Development
- Hypertension Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Late Stage Drug Profiles - Companies
- Aliskiren + Amlodipine + Hydrochlorothiazide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Aliskiren + Valsartan + Hydrochlorothiazide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Aprovel + Amlodipine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BR-A-657 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Citrupress IV - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CS-8635 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Darusentan - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Diupress - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- EUR 1000 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IMD1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Jenloga XR - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MK954 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Olmesartan + Amlodipine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- S-474474 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TAK-491 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TAK-491 + Chlorthalidone - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TAK-491 + Hydrochlorothiazide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TAK-536 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TCV-116 + Actos - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Telmisartan + Simvastatin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Twynsta - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Valsartan + Enalapril - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Late Stage Drug Profiles - Universities/Institutes
- Acetyl-L-Carnitine + Simvastatin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Acetyl-L-carnitine + statin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Allopurinol - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Ambrisentan - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Angiotensin II Type 1 Receptor Antagonists - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Aspirin + Clopidogrel|Other: Target of Blood Pressure|Other: placebo - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Chlorthalidone + Amiloride_ - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Coreg CR + Lisinopril - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Coreg CR + Lisinopril - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Enalapril - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Enalaprilat - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Epidural lidocaine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Imidapril - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Irbesartan - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Isradapine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- L-Arginine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Lisinopril - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- losartan - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Losartan - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Losartan + Hydrochlorothiazide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- N-Nitro L-arginine-methylester - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Nicardipine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Nifedipine + Losartan - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Pioglitazone - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Propranolol - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Ramipril - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Sodium-Lactate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Spironolactone - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Spironolactone - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Telmisartan + Amlodipine + Hydrochlorothiazide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Urapidil - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Valsartan + Lisinopril - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Valsartan + Pravastatin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Valsartan + Simvastatin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Valsartan + Simvastatin + Ezetimibe - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Ventavis - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Discontinued Products
- Hypertension - Featured News
- Oct 12, 2010: Boehringer Ingelheim Receives European Positive Opinion For TWYNSTA For Treatment Of Hypertension
- Aug 31, 2010: Boehringer Ingelheim Reports Combination Therapy Of Telmisartan And Amlodipine Provides Significantly Better BP Lowering Than Either Agent Alone
- Jul 26, 2010: European Committee For Medicinal Products For Human Use (CHMP) Adopts Positive Opinion For TWYNSTA, Boehringer Ingelheim’s New Single Pill Combination Hypertension Treatment
- Jun 21, 2010: Takeda's New Head-to-Head Phase III Study Evaluated Systolic Blood Pressure Reduction Of Azilsartan Medoxomil Compared To Valsartan
- May 03, 2010: Corcept Updates Cushing’s Syndrome Development
- May 03, 2010: Takeda Announces Pivotal Phase III Data Of Azilsartan Medoxomil
- May 01, 2010: New Data Demonstrates Investigational Triple Antihypertensive Combination Therapy Produces Superior Blood Pressure Reductions Compared To Corresponding Dual Treatments
- Apr 27, 2010: Takeda Submits NDA For Azilsartan Medoxomil In US For Treatment Of Hypertension
- Apr 05, 2010: Tioga Signs SPA Agreement With FDA For Phase III Trials Of Asimadoline In Patients with D-IBS
- Mar 17, 2010: Chelsea Reports Findings From Northera 24-Hour Blood Pressure Monitoring Study
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Hypertension, 2010
- Products under Development for Hypertension - Comparative Analysis, 2010
- Comparative Analysis by Late Stage Development, 2010
- Comparative Analysis by Mid Clinical Stage Development, 2010
- Comparative Analysis by Early Clinical Stage Development, 2010
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2010
- Boehringer Ingelheim GmbH, 2010
- Abbott Laboratories, 2010
- Shionogi & Co., Ltd., 2010
- Sanofi-Aventis, 2010
- Gilead Sciences, Inc., 2010
- Daiichi Sankyo Company, Ltd, 2010
- Merck & Co., Inc., 2010
- MicroDose Technologies, Inc., 2010
- Dainippon Sumitomo Pharma Co., Ltd., 2010
- Takeda Pharmaceutical Company Limited, 2010
- Plexxikon Inc., 2010
- Novartis AG, 2010
- Chong Kun Dang Pharmaceutical, 2010
- Daewoong Pharmaceutical Co., Ltd., 2010
- Pfizer Inc., 2010
- Recordati S.p.A., 2010
- Sigma-Tau S.p.A., 2010
- Eurand N.V., 2010
- Ligand Pharmaceuticals Incorporated, 2010
- Medicure Inc., 2010
- Medivir AB, 2010
- NicOx SA, 2010
- Compugen Ltd., 2010
- Palatin Technologies, Inc., 2010
- Yuhan Corporation, 2010
- Boryung Pharmaceutical Co., Ltd., 2010
- Hanall Pharmaceutical Co., Ltd., 2010
- Cytos Biotechnology AG, 2010
- LG Life Sciences, Ltd, 2010
- AFFiRiS AG, 2010
- Respiratorius AB, 2010
- Arete Therapeutics Inc., 2010
- Circ Pharma Limited, 2010
- Surface Logix, Inc., 2010
- QUANTUM GENOMICS Corp., 2010
- Ferrer Internacional S.A., 2010
- Targacept, Inc., 2010
- Bial Group, 2010
- Diakron Pharmaceuticals, Inc., 2010
- Biolink Group AS, 2010
- Cellceutix Pharmaceuticals, Inc., 2010
- KemPharm, Inc., 2010
- Sorbent Therapeutics, Inc., 2010
- Mayo Clinic, 2010
- Eurofarma, 2010
- Asklepion Pharmaceuticals, LLC., 2010
- Serodus AS, 2010
- Assessment by Monotherapy Products, 2010
- Assessment by Combination Products
- Assessment by Stage and Route of Administration, 2010
- Assessment by Molecule Type, 2010
- Discontinued Products
- List of Figures
- Number of Products under Development for Hypertension, 2010
- Products under Development for Hypertension - Comparative Analysis, 2010
- Products under Development by Companies, 2010
- Products under Investigation by Universities/Institutes, 2010
- Late Stage Products, 2010
- Mid Clinical Stage Products, 2010
- Early Clinical Stage Products, 2010
- Discovery and Pre-Clinical Stage Products, 2010
- Assessment by Monotherapy Products, 2010
- Assessment by Combination Products, 2010
- Assessment by Route of Administration, 2010
- Assessment by Stage and Route of Administration, 2010
- Assessment by Molecule Type, 2010
- Assessment by Stage and Molecule Type, 2010
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Hypertension Reports